CLINICAL UTILITY OF TENSIN 2 LEVELS AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN BREAST CANCER

Basit Öğe Kaydı
dc.contributor.authorSerin, Kursat Rahmi
dc.contributor.authorUcuncu, Zubeyr
dc.contributor.authorTemel, M. Kemal
dc.contributor.authorBademler, Suleyman
dc.contributor.authorSoydinc, Hilal Oguz
dc.contributor.authorKaranlik, Hasan
dc.contributor.authorKarabulut, Senem
dc.date.accessioned2024-09-11T19:52:44Z
dc.date.available2024-09-11T19:52:44Z
dc.date.issued2021
dc.departmentİstanbul Gelişim Üniversitesien_US
dc.description.abstractBackground: To discuss the diagnostic and prognostic potential of tensin-2 (TNS2) levels in patients with breast cancer (BC). Methods: The study included sixty patients with BC and twenty healthy female controls for a comparative investigation of TNS2 protein and gene expression levels.. Results: Compared to the healthy controls, we found that the patient group showed a statistically significantly lower mean level of TNS2 protein (p<0.001) and higher mean level of TNS2 gene expression (p=0.015). Secondly, we examined the clinical utility of TNS2 levels as an indicator of invasiveness and aggressiveness in BC by comparing patient TNS2 levels by stage and grade. Although the measured mean values differed between the patients subgrouped by tumor biology, grade, and stage, we found that the differences were not statistically significant. Conclusion: Our findings suggest that TNS2 levels can be utilized diagnostically and prognostically, and that there is a need for further studies with larger he mean values measured differed between the patient subgroups based on tumor elucidate the clinical value of TNS2 protein and gene expression levels as an early prognosticator of aggressiveness in BC and thus a useful criterion in treatment optimization.en_US
dc.description.sponsorshipIstanbul University Agency of Scientific Research Projects [24751]en_US
dc.description.sponsorshipThis study was funded by the Istanbul University Agency of Scientific Research Projects (project no. 24751).en_US
dc.identifier.doi10.19193/0393-6384_2021_1_86
dc.identifier.endpage558en_US
dc.identifier.issn0393-6384
dc.identifier.issn2283-9720
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85101867626en_US
dc.identifier.startpage553en_US
dc.identifier.urihttps://doi.org/10.19193/0393-6384_2021_1_86
dc.identifier.urihttps://hdl.handle.net/11363/8017
dc.identifier.volume37en_US
dc.identifier.wosWOS:000621776000086en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherCarbone Editoreen_US
dc.relation.ispartofActa Medica Mediterraneaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240903_Gen_US
dc.subjectBreast canceren_US
dc.subjectnovel biomarkersen_US
dc.subjecttensinsen_US
dc.subjectTNSen_US
dc.titleCLINICAL UTILITY OF TENSIN 2 LEVELS AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN BREAST CANCERen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu